Syndax initiated with an Outperform at Baird. Baird analyst Madhu Kumar initiated Syndax with an Outperform rating, citing a positive risk/reward, its valuation at cash levels despite having a pivotal asset with FDA Breakthrough Therapy Designation, and its drug pipeline. Kumar has a $30 price target on Syndax shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.